Skip to main contentAI and Advanced
/
WINDLAS · NSEMarket ticker unavailable · configure an authorised index feed
WI
NSE · Equity shares · Biotechnology & Drugs-29.50 · -2.61%
Windlas Biotech WINDLAS
NSE:INR 1,100
BSE:INR 862.65
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for WINDLAS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,129.5
Day rangeINR 1,084 — INR 1,144
52-week rangeINR 697.4 — INR 1,181.9
Volume83,578
Market cap1,845.91
P/E23.36
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)904.09
Net Income (INR Cr)66.46
Rev Growth (5 Year %)16.15
EPS Growth (5 Year %)33.8
P/E Ratio23.36
Book Value271.92
EPS31.15
Price/BV4.05Computed
Research path: Interpret Windlas Biotech's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
WINDLASWindlas Biotech1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 907.35 | 760.45 | 626.21 |
| Accumulated Depreciation Total | -148.16 | -118.61 | -92.06 |
| Cash Equivalents | 0.48 | 0.21 | 0.15 |
| Other Liabilities Total | 3.33 | 2.98 | 2.5 |
| Accrued Expenses | 32.66 | 34.47 | 30.38 |
| Long Term Debt | 0.1 | 0 | 0 |
| Common Stock Total | 10.55 | 10.48 | 10.4 |
| Other Equity Total | -0.05 | -0.05 | -0.04 |
| Other Current Assets Total | 0.03 | 0.18 | 24.92 |
| Prepaid Expenses | 1.39 | 1.05 | 0.98 |
| Total Assets | 907.35 | 760.45 | 626.21 |
| Current Portof LT Debt/Capital Leases | 33.09 | 30.35 | 1.62 |
| Additional Paid-In Capital | 202.91 | 198.94 | 194.6 |
| Cash | 0.51 | 0.42 | 5.27 |
| Total Equity | 580.84 | 505.77 | 449.94 |
| Long Term Investments | 1.75 | 0.97 | 1.98 |
| Retained Earnings(Accumulated Deficit) | 347.76 | 291.15 | 240.09 |
| Total Common Shares Outstanding | 2.11 | 2.1 | 2.08 |
| Property/Plant/Equipment Total-Gross | 414.17 | 340.53 | 272.35 |
| Tangible Book Valueper Share Common Eq | 271.92 | 238.08 | 214.18 |
| Total Liabilities | 326.51 | 254.68 | 176.27 |
| Total Debt | 35.34 | 32.6 | 3.64 |
| Short Term Investments | 278.28 | 238.85 | 199.07 |
| Cashand Short Term Investments | 279.28 | 239.48 | 204.49 |
| Total Receivables Net | 281.52 | 201.15 | 137.71 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Accounts Receivable-Trade Net | 227.83 | 167.45 | 136.94 |
| Property/Plant/Equipment Total-Net | 266.01 | 221.93 | 180.29 |
| Total Current Liabilities | 320.93 | 249.44 | 171.75 |
| Total Inventory | 64.63 | 83.27 | 63.18 |
| ESOP Debt Guarantee | 19.66 | 5.25 | 4.89 |
| Accounts Payable | 238.49 | 167.24 | 131.51 |
| Other Currentliabilities Total | 16.68 | 17.39 | 8.24 |
| Total Long Term Debt | 2.25 | 2.25 | 2.02 |
| Intangibles Net | 6.91 | 6.78 | 4.47 |
| Other Long Term Assets Total | 4.98 | 3.7 | 2.96 |
| Note Receivable-Long Term | 0.85 | 1.94 | 5.22 |
| Total Current Assets | 626.85 | 525.13 | 431.29 |
| Capital Lease Obligations | 2.15 | 2.25 | 2.02 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.71
Price to Sale Ratio2.04
Growth
Debt 5Yr CAGR %1.79
Margins
Operating Margin 12m8.18
Operating Margin 5y Avg8.96
Net Profit Margin 12m7.35
Net Profit Margin 5y8.14
Yield
Dividend Yield %0.72
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk32.17
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,937.6 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,368.55 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,972.75 | 1.68 L | 72.73 | — |
| Cipla | INR 1,409.1 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,121.3 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 63.31%
- FII
- 2.04%
- MF
- 5.76%
- Other
- 28.89%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Shree Cement, Orient Bell among key stocks to trade ex-dividend today on 21 July, 2025Market news · 21 Jul 2025, 9:16 am
Dividend Stocks: Shree Cement and Orient Bell are among the key stocks to trade ex-dividend today on 21 July 2025. Among other stocks to trade ex-date are Acceleratebs India, Anupam Rasayan India, OCCL, Thangamayil Jewellery, and Windlas Biotech. Check dividend payout and other details.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 27 March 2025Market news · 27 Mar 2025, 6:40 am
Sumeet Bagadia recommended buying these seven breakout shares to buy today - Aavas Financiers, Windlas Biotech, HEG, A B Infrabuild, and Elecon Engineering Company.
Breakout stocks to buy: Sumeet Bagadia recommends five shares to buy todayMarket news · 14 Nov 2024, 10:43 am
Breakout stocks to buy: Sumeet Bagadia recommends five shares to buy today — Windsor Machines, TTL, Suven Pharma, Paradeep Phosphates, and Windlas Biotech
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.6.3000 per share(126%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingBuy Back of Shares.
- board MeetingsBuy Back of Shares
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Windlas Biotech
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Windlas Biotech Limited is a domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). Its portfolio of CDMO solutions includes product development, licensing, and commercial manufacturing of complex drugs and dosage forms. Its product development and manufacturing capabilities in complex generic products by developing products, including alternate dosages, such as, medicated mouth sprays; coating technologies, including, pellet coating using bottom spray, API coating, pH dependent coating and nanosized crystals; nutraceuticals dosages, including, biscuits, protein powder, supplements, chocolate bars and malt based foods, and ayurvedic products, such as wellness products, hair oils and cough syrups. Its four fungible, Schedule-M compliant OSD/OLD manufacturing facilities are located in Dehradun, Uttarakhand, India. It specializes in manufacturing formulations, solid pharmaceutical dosage forms, liquid pharmaceutical dosage forms and injectables.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- WINDLAS
- BSE Code
- 543329
Questions
Stock FAQ
What is the symbol and ISIN of Windlas Biotech?
Windlas Biotech has the symbol WINDLAS and ISIN - INE0H5O01029.
What is the current price of Windlas Biotech?
Windlas Biotech is currently trading at INR 1,100.00.
What are the year high and year low of Windlas Biotech?
Windlas Biotech has a year high of INR 1,181.90 and a year low of INR 697.40.
What is the market capitalization of Windlas Biotech?
Windlas Biotech has a market capitalization of INR 1,845.91 crore.
What is the P/E ratio of Windlas Biotech?
Windlas Biotech has a P/E ratio of 23.36.
What is the dividend yield of Windlas Biotech?
Windlas Biotech has a dividend yield of 0.72%.
How is the financial performance of Windlas Biotech based on revenue, net income, and EPS?
Windlas Biotech has revenue of INR 904.09 crore, net income of INR 66.46 crore, and EPS of INR 31.18.
What is the book value of Windlas Biotech?
Windlas Biotech has a book value of INR 271.92.
What is the debt-to-equity ratio of Windlas Biotech?
Windlas Biotech has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Windlas Biotech?
Windlas Biotech has a price-to-book ratio of 4.05 and a price-to-sales ratio of 2.04.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.